Innovation and investment for the future of healthcare THURSDAY, SEPTEMBER 28TH, 6-9PM
in Partnership with
Organised by: Hosted by:
Wharton Alumni Angels Network and Biotech and Money present: The Digital Health Revolution
18:00 – 18:45: Registration and welcome drinks
18:45 – 19:45: Panel Discussion
The Digital Health Revolution: Innovation and investment for the future of healthcare
- Concept to Commercialization: how digital health start-ups can successfully pilot, partner, raise funding and bring new technologies to the global marketplace
- Investment Landscape: what should investors consider when looking to invest in digital health start-ups?
19:45 – 20:00: Audience Q&A
20:00 – 21:00: Networking drinks
Location: Cocoon Networks, 4 Christopher St., London EC2A 2BS. Kind sponsor of the venue.
Ticket Price: £24 for Wharton Alumni and Biotech and Money members, if you are a Biotech and Money Partner, eligible for free tickets as part of your agreement, please register via: Partner Ticket
Dr. Andy Richards CBE, Biotechnology Entrepreneur and Business Angel
Andy is an entrepreneur and business angel with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Slience Therapeutics plc, Cancer Rsearch Technology (commercial arm of CR-UK), Cambridge Temperature Concepts, and Cambridge University Hospitals NHS Foundationn Trust. He is an advisor to Cambridge Innovation Capital and the UCL technology fund. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.
Dr. Vishal Gulati, HealthTech Venture Partner, Draper Esprit
Dr. Vishal Gulati is one of the Europe’s leading digital healthcare investors. Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. He is currently on the boards of Horizon Discovery PLC and EcoEos. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis. He has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics. Previously, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital.
Andy Blackwell, CSO, Ieso Digital
Andy is the Chief Scientific Officer at Ieso Digital Health and a Non-Executive Director at Cambridge Cognition Plc. He specialises in the development and application of digital technology to understand, prevent, diagnose, monitor and treat conditions affecting mental health. In July 2015 Andy became a Non-Executive Director at Cambridge Cognition Plc and joined the team at Ieso Digital Health, a rapidly growing mental health therapy company using unique breakthrough technology to improve patient lives and to enhance the efficiency and economics of healthcare delivery.
Dan Vahdat, CTO, Medopad
Dan is CTO and Co-founder of Medopad, which has developed a unique platform of remote monitoring apps, mobile technology and advanced analytics to deliver a personalized, more efficient healthcar experience. Medopad is leveraging the latest machine learning technologies to address the cchallenges associated with injury detection and preventation healthcare. KPMG recently named Medopad a $1B HealthTech company in the making. Dan drives product vision, technology and strategy at Medopad. Dan’s professional career spans from IT to medical technology, and he is an award winning innovator in the fields of science and technology.
James Shaw, Founder. JAG Shaw Baker
James is a leading transactional venture capital lawyer, advising entrepreneurs, companies and investors through the funding life-cycle. Since qualifying as a lawyer in 2000, James has helped entrepreneurs, high-growth technology based companies and investors navigate their way through multiple rounds of financing, growth, scale-up and ultimately exit/liquidity event. Over the years, James has also been one of the most prolific University spin-out lawyers to life sciences companies and continues to advise on spin-out activity.
Tickets are non-refundable but are transferable to a nominated Wharton Club Member of your choice, so long as your nomination reaches firstname.lastname@example.org by 5pm two days before the event.
Any technical issues with the website should be addressed to email@example.com